ArticleFrontiers in endocrinology2026
Development of a risk stratification tool for rapidly progressive diabetic retinopathy in type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The progression of rapidly progressive diabetic retinopathy (PDR) in type 2 diabetes mellitus (T2DM) is characterized by substantial inter-individual variability. To develop and validate a nomogram for individualized risk prediction and stratification of rapidly progressive PDR in T2DM by incorporating diabetes duration, glycated hemoglobin (HbA1c), 24-hour urinary protein quantification, growth differentiation factor 15 (GDF15), Diabetic Retinopathy Severity Scale (DRSS) grade, and foveal avascular zone area. Methods: This retrospective study enrolled 342 patients with T2DM (1999 WHO criteria), randomly assigned to training (n=240) and validation (n=102) sets (7:3 ratio). Baseline demographic, clinical, metabolic, renal, inflammatory biomarker, and ophthalmic imaging data were collected. Predictive variables were selected via univariate analysis and least absolute shrinkage and selection operator (LASSO) regression. Independent predictors identified by multivariable logistic regression were incorporated into a nomogram. For comparison, Random Forest, multivariable logistic regression, and Gradient Boosting Machine models were also developed. Model performance was assessed using the area under the receiver operating characteristic curve (AUC-ROC), calibration curves, and decision curve analysis (DCA). Results: Univariate analysis identified six significant factors (all Conclusion: A novel risk prediction model for rapidly progressive PDR in T2DM was developed and validated by integrating multidimensional parameters. Demonstrating favorable discrimination, calibration, and clinical utility, this model provides a promising tool for early identification of high-risk individuals and optimization of personalized intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.